When This Dancer Got Out of Step With Her Body Due to PCOS, She Turned to Allara for Help

The Story: A Dancer's Body, a Hormonal Rebellion

Dance is a sport that demands total body awareness. Rhythm, line, weight distribution, recovery. When something goes wrong internally, performers feel it before any lab value confirms it.

For this dancer, the signals started subtly. Periods that had always run like clockwork became erratic, then disappeared for stretches of three or four months. A few extra pounds appeared around the abdomen despite no change in training volume or diet. Skin that had been clear through her teenage years broke out along the jawline and chin. Energy, which dancers depend on as much as technique, became unpredictable. Some mornings she woke foggy and heavy. Others she felt wired but could not recover from rehearsal the way she used to.

She was in her mid-twenties and at the peak of her career. None of this made sense.

Why PCOS Is Easy to Miss in Active Women

Physicians often attribute irregular cycles in dancers and endurance athletes to hypothalamic amenorrhea, a condition caused by low energy availability rather than hormonal excess. The two look similar on the surface. Both produce missed periods. But their hormonal signatures differ, and treating hypothalamic amenorrhea with the tools designed for PCOS, or vice versa, can make things worse.

PCOS involves elevated androgens, insulin resistance, and in many cases polycystic ovarian morphology on ultrasound. Hypothalamic amenorrhea involves suppressed LH, low estrogen, and normal or low androgens. The dancer's labs eventually told the right story: elevated free testosterone, an LH:FSH ratio above 2:1, and fasting insulin of 18 mU/L at a fasting glucose of 92 mg/dL, a combination pointing squarely at insulin resistance-driven PCOS rather than energy deficiency.

The Delay Between Symptoms and Diagnosis

Research published in Human Reproduction found that women with PCOS wait an average of 2 years and see an average of 3 physicians before receiving an accurate diagnosis. [1] This dancer's timeline was similar. She had been told she was "just stressed," advised to eat more, and once prescribed a short course of progesterone to trigger a withdrawal bleed, without anyone ordering a testosterone level.

Delayed diagnosis is not trivial. Each year of unmanaged insulin resistance raises her long-term risk of type 2 diabetes. The Nurses' Health Study II showed that women with PCOS have a 2.2-fold higher risk of developing type 2 diabetes compared with age-matched controls. [2]

What PCOS Actually Does to the Body

PCOS is not simply a reproductive disorder. It is a metabolic and endocrine condition that happens to express itself most visibly through reproductive symptoms. Understanding the biology explains why a dancer's performance, mood, body composition, and menstrual pattern can all deteriorate at once.

The Androgen Excess Mechanism

In a healthy ovulatory cycle, the pituitary releases FSH and LH in a coordinated pulse pattern. FSH stimulates follicle maturation; LH triggers ovulation. In PCOS, LH pulse frequency is elevated, which drives the theca cells of the ovary to produce excess androgens, primarily testosterone and androstenedione. Those androgens partially convert to estrogen in fat tissue, but the ratio remains abnormal.

The result: follicles begin to develop but stall before reaching the dominant phase required for ovulation. They accumulate as small cysts on the ovary's outer rim. Cycles become long, irregular, or absent. [3]

Excess testosterone also binds to androgen receptors in the skin and hair follicles, producing acne on the lower face and neck, and in some women, hair thinning at the temples or crown.

Insulin Resistance and the Feedback Loop

Insulin resistance worsens the androgen picture. Elevated insulin signals the ovaries to produce even more testosterone and suppresses hepatic synthesis of sex hormone-binding globulin (SHBG). Lower SHBG means more free, biologically active testosterone circulates. This creates a self-amplifying cycle: more insulin resistance drives more androgen, which disrupts ovulation, which alters body composition, which worsens insulin sensitivity further. [4]

For a dancer, this loop has direct performance consequences. Unstable blood glucose between meals drives energy crashes. Elevated cortisol, common in women with untreated PCOS, impairs recovery. Disrupted sleep architecture, reported by up to 35% of women with PCOS in a survey published in the Journal of Clinical Sleep Medicine, reduces the growth hormone release needed for muscle repair overnight. [5]

Inflammation: The Underappreciated Driver

Chronic low-grade inflammation is present in PCOS independent of body weight. C-reactive protein (CRP) levels are elevated even in lean women with PCOS. [6] Inflammation inhibits insulin signaling at the receptor level, adding another mechanism for insulin resistance that lifestyle changes alone may not fully address.

Diagnosing PCOS: What the Rotterdam Criteria Actually Require

The Rotterdam criteria, established in 2003 and still endorsed by the Endocrine Society's 2023 guidelines, require two of the following three features. [7]

1. Oligo-ovulation or anovulation (cycles longer than 35 days, or fewer than 9 cycles per year)
2. Clinical or biochemical signs of hyperandrogenism (elevated free testosterone, or acne, hirsutism, alopecia on exam)
3. Polycystic ovarian morphology on ultrasound (12 or more follicles measuring 2 to 9 mm in diameter, or ovarian volume above 10 mL)

Other causes, including thyroid dysfunction, congenital adrenal hyperplasia, hyperprolactinemia, and Cushing's syndrome, must be excluded before confirming PCOS. The dancer's workup included TSH, prolactin, 17-hydroxyprogesterone, and a 24-hour urinary cortisol to rule each of these out.

Lab Values That Matter Most

| Lab | Normal Range | PCOS Concern Threshold | |---|---|---| | Free testosterone | 0.3 to 1.9 ng/dL | >1.9 ng/dL or elevated by assay | | SHBG | 18 to 144 nmol/L | <30 nmol/L in premenopausal women | | LH:FSH ratio | ~1:1 | >2:1 (suggestive, not diagnostic) | | Fasting insulin | 2 to 20 mU/L | >15 mU/L with fasting glucose <100 mg/dL | | AMH | Age-dependent | Often elevated in PCOS; >4.7 ng/mL |

The dancer's AMH came back at 6.1 ng/mL, consistent with a large antral follicle count, and her free testosterone was 2.4 ng/dL. Two of the three Rotterdam criteria were met without needing an ultrasound.

Evidence-Based Treatment Options for PCOS

No single treatment addresses every facet of PCOS, because PCOS itself has multiple phenotypes. The correct protocol depends on the woman's primary concerns: cycle regularity, fertility, metabolic health, skin symptoms, or a combination.

Lifestyle Modification: The Starting Point

The Endocrine Society's 2023 PCOS guideline states that lifestyle changes are the first-line treatment for overweight or obese women with PCOS, and remain beneficial at any weight for metabolic outcomes. [7] A weight reduction of 5 to 10% of body weight restores ovulation in roughly 55 to 60% of anovulatory women with PCOS, based on a randomized trial published in The Journal of Clinical Endocrinology and Metabolism. [8]

For a dancer whose training load is already high, "more exercise" is rarely the answer. The target instead is dietary quality: reducing glycemic load, emphasizing protein at each meal to blunt postprandial insulin spikes, and avoiding the chronic energy restriction that would tip the condition into hypothalamic overlap.

A Mediterranean-pattern diet reduced fasting insulin by 22% and improved menstrual frequency within 12 weeks in a controlled trial of 96 women with PCOS. [9]

Metformin: Mechanism and Evidence

Metformin reduces hepatic glucose output and improves peripheral insulin sensitivity. In PCOS, it lowers circulating insulin, which secondarily reduces ovarian androgen production and can restore LH pulse regularity.

A Cochrane systematic review of 40 randomized controlled trials found that metformin improved ovulation rates (odds ratio 2.55, 95% CI 1.54 to 4.23) compared with placebo, and improved cycle regularity in women who were not seeking immediate fertility. [10] Standard dosing begins at 500 mg once daily with food and titrates to 1,500 to 2,000 mg/day over 4 to 8 weeks to minimize gastrointestinal side effects.

Metformin is not FDA-approved specifically for PCOS but is used off-label under Endocrine Society and ACOG guidance. [7, 11]

Hormonal Contraception for Cycle Regulation and Androgen Suppression

Combined oral contraceptives (OCPs) containing ethinyl estradiol plus a progestin with low androgenic activity, such as norgestimate or desogestrel, reduce free testosterone by raising SHBG, suppress LH-driven androgen production, and create predictable withdrawal bleeds.

A trial published in Fertility and Sterility comparing OCP monotherapy with metformin monotherapy found OCPs superior for reducing hirsutism scores (modified Ferriman-Gallwey score decreased by 4.2 points vs. 1.8 points at 6 months, P<0.01). [12] For the dancer, whose primary symptoms were skin-related and cycle-related rather than fertility-related, a low-androgen OCP became part of her plan alongside metformin.

Inositol: The Supplement With Actual Data

Myo-inositol acts as an insulin sensitizer through a distinct mechanism from metformin, functioning as a second messenger in the insulin signaling pathway. A meta-analysis of 13 randomized controlled trials (N = 1,132) published in Reproductive Biology and Endocrinology found myo-inositol significantly reduced fasting insulin (standardized mean difference -0.97, P<0.001), improved menstrual regularity, and modestly reduced free testosterone. [13]

The typical dose is 2,000 to 4,000 mg of myo-inositol daily, often combined with 200 to 400 mcg of D-chiro-inositol in a 40:1 ratio. This combination may more closely mimic the physiological ratio found in ovarian tissue.

GLP-1 Receptor Agonists: Emerging Evidence

Semaglutide and liraglutide are not currently FDA-approved specifically for PCOS, but data are accumulating. A 2023 study in Obesity found that semaglutide 1.0 mg weekly reduced body weight by 11.4% over 24 weeks in women with PCOS and a BMI above 27, with parallel reductions in free testosterone, fasting insulin, and LH:FSH ratio. [14]

The clinical decision of when to add a GLP-1 receptor agonist to a PCOS regimen depends on several factors that a supervising physician should assess: fasting insulin above 15 mU/L at a normal fasting glucose, BMI above 27 with failed lifestyle modification after 3 to 6 months, or co-existing impaired fasting glucose (100 to 125 mg/dL). This framework does not replace individualized clinical judgment but provides a structured starting point.

Spironolactone for Androgen-Driven Skin and Hair Symptoms

Spironolactone at doses of 50 to 200 mg/day blocks androgen receptors in the skin and is widely used for hirsutism and hormonal acne when OCPs alone are insufficient. A randomized trial in JAMA Dermatology found that spironolactone 100 mg/day reduced inflammatory acne lesion count by 54% at 6 months compared with 35% for placebo (P<0.001). [15] Because spironolactone is teratogenic, it must be paired with reliable contraception in women who could become pregnant.

How Allara Addresses PCOS Specifically

Allara Health is a telehealth platform built around women's hormonal conditions, with PCOS as its primary clinical focus. Its model pairs patients with OB/GYN or endocrinology-trained physicians who order a structured PCOS-specific lab panel, review imaging if needed, and design individualized treatment plans. Follow-up is conducted via video visits and asynchronous messaging, which fits the scheduling demands of a professional performer.

For the dancer, the process started with a 45-minute intake visit. Labs were ordered through a national reference lab with a mobile draw option. Within two weeks she had her diagnosis confirmed, a prescription for metformin 500 mg titrating to 1,500 mg over 6 weeks, a low-androgen OCP, and a dietary consult referral focused on glycemic load rather than caloric restriction.

What Changed Over Six Months

Three months into treatment, her cycle returned at 32 days. Acne along the jawline cleared by about 70%. Fasting insulin dropped from 18 mU/L to 11 mU/L. Energy during afternoon rehearsals stabilized.

At six months, she reported the first period she had experienced without any pharmacologic trigger in over two years. Body weight was unchanged, which was the goal: her training load meant that weight loss was not the target. Hormonal stabilization without compromising performance nutrition was.

PCOS and the Athlete: Special Considerations

Energy Availability Is Non-Negotiable

The line between PCOS and hypothalamic amenorrhea can blur in athletes, particularly dancers who operate under aesthetic pressure to maintain low body weight. Aggressive caloric restriction drops leptin, suppresses GnRH pulsatility, and can produce a secondary hypothalamic overlay on top of existing PCOS. Treating this requires increasing energy intake before metabolic PCOS therapies can work effectively.

The Female Athlete Triad Coalition defines low energy availability as intake below 30 kcal/kg of fat-free mass per day. [16] A sports dietitian who understands hormonal conditions should be part of any PCOS management plan for competitive athletes.

Mental Health Screening Is Part of the Protocol

PCOS is associated with a 3-fold higher prevalence of depression and a 5-fold higher prevalence of anxiety compared with age-matched women without the condition, based on a meta-analysis of 18 studies published in Psychoneuroendocrinology. [17] For a performer whose livelihood depends on confidence, presence, and emotional regulation, untreated mood symptoms can be as career-limiting as physical ones. Screening tools like the PHQ-9 and GAD-7 should be administered at baseline and at each follow-up visit.

Bone Health in Anovulatory Athletes

Prolonged anovulation, whether from PCOS, hypothalamic suppression, or both, reduces estrogen-driven bone remodeling. The IOC Medical Commission's 2023 consensus statement on Relative Energy Deficiency in Sport (RED-S) lists amenorrhea exceeding 3 months as an indication for bone density assessment via DEXA scan. [18] For the dancer, her DEXA at baseline showed a lumbar spine Z-score of -1.1, within normal limits but worth monitoring annually given ongoing anovulatory history.

What to Expect from PCOS Treatment Over Time

PCOS does not resolve after a course of antibiotics or a month of a new medication. It is a chronic condition requiring ongoing management as life circumstances shift: training volume, stress load, reproductive goals, and metabolic risk all evolve.

Short-Term Benchmarks (0 to 6 Months)

Cycle regularity is the most visible benchmark. Expect 2 to 4 months of treatment before reliable cycles return on metformin alone. OCPs produce cycle regularity immediately but mask whether the underlying disorder is improving. Lab reassessment of fasting insulin, free testosterone, and SHBG at 3 months gives a clearer metabolic picture.

Long-Term Monitoring (Annual)

The Endocrine Society recommends annual fasting glucose and a lipid panel in all women with PCOS, given the 2 to 4-fold increased risk of metabolic syndrome. [7] Women with impaired fasting glucose at baseline should receive a 75 g oral glucose tolerance test (OGTT) to rule out glucose intolerance or early type 2 diabetes. Women with PCOS who are above age 35 or who have a BMI above 30 should also receive a hemoglobin A1c, per the American Diabetes Association's 2024 Standards of Care. [19]